The company emerged Bioaptus of opportunity identified in the laboratory medicine market in Brazil: the supply of monoclonal antibodies. About 99% of the antibodies used for diagnosis and treatment of diseases in Brazil are imported.


The Bioaptus developed a technology which allows the production of antibodies without the use of cells or immunization of animals. This is the ANFITECH® Platform, a synthetic antibody that behaves similarly to monoclonal antibodies. Our company is a pioneer in this sector.


Here the life science market (Life Science) innovative solutions for the development of synthetic antibodies. Through this technology a researcher You can customize a specific ANFITECH antibody to the protein target your search online.